// App-Quantinova.ai

P2-16-15 : 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study

Researchers

Presenter

  • Chara Stavraka

Principal Investigators

  • T. R. Jeffry Evans

  • Joanna Dunlop

  • Helena Earl

  • David A. Cameron

  • Robert E Coleman

  • Timothy Perren

  • Robert CF Leonard

  • Janine L Mansi

Medical Centers

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Institute of Cancer Sciences, CR-UK Beatson Institute, Glasqow, United Kingdom

  • Scottish Clinical Trials Research Unit (SCTRU), NHS National Services Scotland, Edinburgh, UK., Edinburgh, United Kingdom

  • University of Cambridge, Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom

  • Cancer Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital,, Edinburgh, United Kingdom

  • Department of Oncology and Metabolism, University of Sheffield, Western Bank, Sheffield S10 2TN, UK., Sheffield, United Kingdom

  • St James's Institute of Oncology, St. James's University Hospital, West Yorkshire, United Kingdom

  • Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Doxorubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved